WO2014033551A3 - The use of direct thrombin inhibitors in critically ill patients - Google Patents

The use of direct thrombin inhibitors in critically ill patients Download PDF

Info

Publication number
WO2014033551A3
WO2014033551A3 PCT/IB2013/002661 IB2013002661W WO2014033551A3 WO 2014033551 A3 WO2014033551 A3 WO 2014033551A3 IB 2013002661 W IB2013002661 W IB 2013002661W WO 2014033551 A3 WO2014033551 A3 WO 2014033551A3
Authority
WO
WIPO (PCT)
Prior art keywords
need
critically ill
direct thrombin
ill patients
anticoagulation
Prior art date
Application number
PCT/IB2013/002661
Other languages
French (fr)
Other versions
WO2014033551A2 (en
WO2014033551A9 (en
Inventor
Dietmar FRIES
Werner STREIF
Original Assignee
Medizinische Universitaet Innsbruck
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medizinische Universitaet Innsbruck filed Critical Medizinische Universitaet Innsbruck
Publication of WO2014033551A2 publication Critical patent/WO2014033551A2/en
Publication of WO2014033551A3 publication Critical patent/WO2014033551A3/en
Publication of WO2014033551A9 publication Critical patent/WO2014033551A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present disclosure is directed to methods of achieving anticoagulation in a patient in need thereof. The typical patient is expected to be in need for anticoagulation treatment for an extended period of time, and therefore has an increased risk of developing heparin resistance. The method comprises administering a therapeutically effective amount of a direct thrombin inhibitor, such as argatroban. The disclosed methods are particularly suited for the treatment of critically ill patients who are expected to be in the need for an extended period of anticoagulation treatment, including but not limited to, ICU patients, and/or patients suffering from sepsis, SIRS, MODS, and/or MOF.
PCT/IB2013/002661 2012-08-31 2013-08-30 The use of direct thrombin inhibitors in critically ill patients WO2014033551A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261743329P 2012-08-31 2012-08-31
US61/743,329 2012-08-31

Publications (3)

Publication Number Publication Date
WO2014033551A2 WO2014033551A2 (en) 2014-03-06
WO2014033551A3 true WO2014033551A3 (en) 2014-04-17
WO2014033551A9 WO2014033551A9 (en) 2014-11-06

Family

ID=49955395

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/002661 WO2014033551A2 (en) 2012-08-31 2013-08-30 The use of direct thrombin inhibitors in critically ill patients

Country Status (1)

Country Link
WO (1) WO2014033551A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040214756A1 (en) * 1993-05-25 2004-10-28 Aventis Behring Gmbh Pharmaceuticals for treating sepsis and septic shock

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040214756A1 (en) * 1993-05-25 2004-10-28 Aventis Behring Gmbh Pharmaceuticals for treating sepsis and septic shock

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANDREAS KOSTER ET AL: "Management of heparin resistance during cardiopulmonary bypass: The effect of five different anticoagulation strategies on hemostatic activation", JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, vol. 17, no. 2, 1 April 2003 (2003-04-01), pages 171 - 175, XP055101763, ISSN: 1053-0770, DOI: 10.1053/jcan.2003.42 *
BEYER J ET AL: "Influence of antithrombin and argatroban on disseminated intravascular coagulation parameters in a patient with septic shock", THROMBOSIS RESEARCH, TARRYTOWN, NY, US, vol. 124, no. 3, 1 July 2009 (2009-07-01), pages 383 - 386, XP026283435, ISSN: 0049-3848, [retrieved on 20081205], DOI: 10.1016/J.THROMRES.2008.10.010 *
FERGUSON L M ET AL: "Recurring extracorporeal circuit clotting during continuous renal replacement therapy in fungal sepsis: Successful treatment with Argatroban", AMERICAN JOURNAL OF THE MEDICAL SCIENCES 2013 LIPPINCOTT WILLIAMS AND WILKINS USA, vol. 345, no. 3, March 2013 (2013-03-01), pages 256 - 258, XP002720210, ISSN: 0002-9629 *
FRANCOIS FOURRIER ET AL: "Double-blind, Placebo-controlled Trial of Antithrombin III Concentrates in Septic Shock With Disseminated Intravascular Coagulation", CHEST, 1 January 1993 (1993-01-01), pages 882 - 888, XP055101801, Retrieved from the Internet <URL:http://journal.publications.chestnet.org/data/Journals/CHEST/20382/882.pdf> [retrieved on 20140212] *
INMAN KRISTIN R ET AL: "Use of subcutaneous lepirudin in an obese surgical intensive care unit patient with heparin resistance", THE ANNALS OF PHARMACOTHERAPY, 1542-6270, CINCINNATI, OHIO, USA, vol. 43, no. 10, 1 October 2009 (2009-10-01), pages 1714 - 1718, XP008167331, ISSN: 1542-6270, DOI: 10.1345/APH.1M169 *
NAITO K ET AL: "Four cases of thrombotic events associated with neuro-endovascular therapy: Heparin resistance and aspirin resistance", INTERVENTIONAL NEURORADIOLOGY 200703 IT, vol. 13, no. SUPPL. 1, March 2007 (2007-03-01), pages 131 - 134, XP008167334, ISSN: 1123-9344 *

Also Published As

Publication number Publication date
WO2014033551A2 (en) 2014-03-06
WO2014033551A9 (en) 2014-11-06

Similar Documents

Publication Publication Date Title
MX2021010672A (en) Diagnosis and therapy of cancer involving cancer stem cells.
WO2014004993A3 (en) Methods of reducing ldl-p
WO2015031808A3 (en) Diagnostic methods and compositions for treatment of glioblastoma
WO2014062720A3 (en) Methods of treating cancer
EA201101117A1 (en) DPP-4 INHIBITORS FOR THE TREATMENT OF DIABETES IN CHILDREN
MX2016006252A (en) Treatment or prevention of pulmonary conditions with carbon monoxide.
EA201400119A1 (en) PHARMACEUTICAL COMPOSITION, METHODS OF TREATMENT AND THEIR APPLICATION
EA201790398A1 (en) METHODS OF TREATING LIVER DISEASES
PH12015502042A1 (en) Use of linagliptin in cardio-and renoprotective antidiabetic therapy
WO2015013635A3 (en) Inhibitors of transcription factors and uses thereof
TR201904980T4 (en) Pharmaceutical combinations comprising a B-Raf inhibitor, an EGFR inhibitor and optionally a PI3K-alpha inhibitor.
EA201691155A1 (en) COMBINATION INHIBITORS OF HISTONDEACETYLASE AND IMMUNOMODULATING MEDICINES
IN2014MN02089A (en)
WO2013024282A3 (en) Inhibitor or down- regulator of the expression of one or both of tbk1 ikk-epsilon for use in the treatment of pi3kinase dependent cancer
WO2011115712A3 (en) Tfpi inhibitors and methods of use
EA201101568A1 (en) TREATMENT OF EX VIVO IMMUNOLOGICAL DISORDERS THROUGH PKC-TETA INHIBITORS
WO2015067755A3 (en) Novel methods and antibodies for treating coagulapathy
WO2013086260A3 (en) Combination therapy for treatment of cancer
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
EA201600288A1 (en) SUBSTITUTED PHYLALANINE DERIVATIVES
CA2863106A1 (en) Hbv immunocomplexes for response prediction and therapy monitoring of chronic hbv patients
IN2014DN08385A (en)
WO2013057592A3 (en) Treatment of sickle cell disease
GB201205739D0 (en) Treatment of acute inflammation in the respiratory tract
FI20115165A0 (en) Therapeutic and diagnostic methods

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13820871

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13820871

Country of ref document: EP

Kind code of ref document: A2